Medical treatment of biliary tract cancer: from peri-operative to palliative care, what's on?

被引：0

作者：

Boucher, E. ^{[1
]}

机构：

[1] Ctr Eugene Marquis, CS 44229, F-35042 Rennes, France

来源：

ONCOLOGIE | 2012年 / 14卷 / 03期

关键词：

Biliary tract cancer; Medical treatment; Perioperative treatment; Palliative therapy; Chemotherapy; Radiotherapy; PHASE-II TRIAL; UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA; QUALITY-OF-LIFE; GALLBLADDER CANCER; HILAR CHOLANGIOCARCINOMA; BILE-DUCT; LIVER-TRANSPLANTATION; NEOADJUVANT CHEMORADIATION; ADJUVANT CHEMOTHERAPY; PHOTODYNAMIC THERAPY;

D O I：

10.1007/s10269-012-2135-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biliary tract cancers (BTCs) encompass different cancers: intrahepatic, Katskin tumor, gallbladder, and main bile duct cancer. Surgical management of these cancers is difficult and most patients with BTC are likely to present with an unresectable or metastatic disease. Although standard systemic chemotherapy approaches are emerging, the prognosis remains poor. Development of adaptive therapeutic strategies is ongoing, as a better knowledge about these tumors is emerging.

引用

页码：150 / 157

页数：8

共 39 条

[31] From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care [J].

Curigliano, Giuseppe ;

Cardoso, Fatima ;

Costa, Alberto ;

Galimberti, Viviana ;

Goldhirsch, Aron ;

Pelicci, Pier Giuseppe ;

Veronesi, Paolo ;

Viale, Giuseppe ;

Orecchia, Roberto .

BREAST, 2017, 31 :241-243

[32] CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy [J].

Lee, Dae-Won ;

Im, Seock-Ah ;

Kim, Yu Jung ;

Yang, Yaewon ;

Rhee, Jiyoung ;

Na, Im Ii ;

Lee, Kyung-Hun ;

Kim, Tae -Yong ;

Han, Sae -Won ;

Choi, In Sil ;

Oh, Do-Youn ;

Kim, Jee Hyun ;

Kim, Tae -You ;

Bang, Yung-Jue .

CANCER RESEARCH AND TREATMENT, 2017, 49 (03) :807-815

[33] Clinical outcomes of second-line chemotherapy after gemcitabine and cisplatin plus S-1 treatment for patients with advanced biliary tract cancer in the KHBO1401-3A study [J].

Shindo, Yoshitaro ;

Nagano, Hiroaki ;

Kanai, Masashi ;

Kobayashi, Shogo ;

Wada, Hiroshi ;

Sakai, Daisuke ;

Eguchi, Hidetoshi ;

Baba, Hideo ;

Kamachi, Hirofumi ;

Takayama, Tadatoshi ;

Ueno, Masaki ;

Takahashi, Masahiro ;

Nakagami, Yuki ;

Yoshimura, Kenichi ;

Hatano, Etsuro ;

Ioka, Tatsuya .

ONCOLOGY REPORTS, 2023, 49 (02)

[34] Cancer survivor late-effects, chronic health problems after cancer treatment: what's the evidence from population and registry data and where are the gaps? [J].

Faithfull, Sara ;

Greenfield, Diana .

CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2024, 18 (01) :55-64

[35] What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?-Results from the lung cancer economics and outcomes research (LUCEOR) study [J].

Lester, J. F. ;

Agulnik, J. ;

Akerborg, O. ;

Chouaid, C. ;

De Geer, A. ;

Finnern, H. W. ;

Herder, G. J. M. ;

Lungershausen, J. ;

Mitchell, P. L. R. ;

Vansteenkiste, J. ;

Ziske, C. ;

Goker, E. .

LUNG CANCER, 2013, 82 (01) :128-135

[36] 5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer [J].

Mitsunaga, Shuichi ;

Ikeda, Masafumi ;

Nomura, Shogo ;

Morizane, Chigusa ;

Todaka, Akiko ;

Yamamoto, Naoto ;

Kamata, Ken ;

Yanagibashi, Hiroo ;

Mizuno, Nobumasa ;

Kawamoto, Yasuyuki ;

Gotoh, Kunihito ;

Shirakawa, Hirofumi ;

Okano, Naohiro ;

Nomura, Tatsuya ;

Tanaka, Kazunari ;

Takahashi, Amane ;

Yagi, Shintaro ;

Ohta, Koji ;

Takayama, Yukiko ;

Miwa, Haruo ;

Nagano, Hiroaki ;

Kojima, Yasushi ;

Hisano, Terumasa ;

Tahara, Munenori ;

Sakuma, Yasunaru ;

Arai, Hiroyuki ;

Nakamura, Ikuo ;

Katayama, Hiroshi ;

Konishi, Masaru ;

Ueno, Makoto .

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2024,

[37] Single-institution experience with gemcitabine–cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine–S-1 combination therapy: a prospective feasibility study [J].

Ryusei Matsuyama ;

Daisuke Morioka ;

Ryutaro Mori ;

Seigo Hiratani ;

Yasuhiro Yabushita ;

Yohei Ota ;

Takafumi Kumamoto ;

Koichi Taniguchi ;

Itaru Endo .

Cancer Chemotherapy and Pharmacology, 2018, 81 :949-955

[38] Spiritual well-being and quality of life among Icelanders receiving palliative care: data from Icelandic pilot-testing of a provisional measure of spiritual well-being from the European Organisation for Research and Treatment of Cancer [J].

Asgeirsdottir, G. H. ;

Sigurdardottir, V. ;

Gunnarsdottir, S. ;

Sigurbjornsson, E. ;

Traustadottir, R. ;

Kelly, E. ;

Young, T. ;

Vivat, B. .

EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (02)

[39] 5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1) [J].

Mitsunaga, Shuichi ;

Ikeda, Masafumi ;

Nomura, Shogo ;

Morizane, Chigusa ;

Todaka, Akiko ;

Yamamoto, Naoto ;

Kamata, Ken ;

Yanagibashi, Hiroo ;

Mizuno, Nobumasa ;

Kawamoto, Yasuyuki ;

Gotoh, Kunihito ;

Shirakawa, Hirofumi ;

Okano, Naohiro ;

Nomura, Tatsuya ;

Tanaka, Kazunari ;

Takahashi, Amane ;

Yagi, Shintaro ;

Ohta, Koji ;

Takayama, Yukiko ;

Miwa, Haruo ;

Nagano, Hiroaki ;

Kojima, Yasushi ;

Hisano, Terumasa ;

Tahara, Munenori ;

Sakuma, Yasunaru ;

Arai, Hiroyuki ;

Nakamura, Ikuo ;

Katayama, Hiroshi ;

Konishi, Masaru ;

Ueno, Makoto ;

Japan Clinical Oncology Grp JCOG HBPOG .

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2024, 31 (12) :886-896

← 1 2 3 4 →